- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
Setting: Primary care
The first level of healthcare, including general medical services, such as family medicine
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Human metapneumovirus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Human metapneumovirus infection
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Adolescents (12-17 years)
- Children (1-11 years)
- People at high risk of STIs
- Men who have sex with men
- Primary care
- Monkeypox virus
- Mpox
- Sexually transmitted infection
- Adults (18-64 years)
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Immunomodulator
- Colchicine
- Metformin
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- PrEP users
- Hospital
- Community
- Primary care
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Treponema pallidum
- Sexually transmitted infection
- Syphilis
- Pharmacological intervention
- PrEP-bSTI